Northern Trust
IMUC

Northern Trust’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Northern Trust’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,093
Closed -$10K – 4279
2016
Q3 		$10K Hold
2,093
– – ﹤0.01% 4136
2016
Q2 		$19K Hold
2,093
– – ﹤0.01% 4125
2016
Q1 		$24K Hold
2,093
– – ﹤0.01% 4117
2015
Q4 		$30K Hold
2,093
– – ﹤0.01% 4132
2015
Q3 		$35K Hold
2,093
– – ﹤0.01% 4136
2015
Q2 		$40K Sell
2,093
-382
-15% -$7.35K ﹤0.01% 4094
2015
Q1 		$48K Hold
2,475
– – ﹤0.01% 4158
2014
Q4 		$72K Hold
2,475
– – ﹤0.01% 4042
2014
Q3 		$88K Sell
2,475
-7
-0.3% -$270 ﹤0.01% 4045
2014
Q2 		$111K Sell
2,482
-12
-0.5% -$579 ﹤0.01% 3990
2014
Q1 		$122K Buy
2,494
+94
+4% +$4.6K ﹤0.01% 3901
2013
Q4 		$89K Buy
2,400
+206
+9% +$19.5K ﹤0.01% 3887
2013
Q3 		$226K Sell
2,194
-10,494
-83% -$1.15M ﹤0.01% 3639
2013
Q2 		$984K Buy
+12,688
New +$1.22M ﹤0.01% 3277

Other funds holding IMUC

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Northern Trust's IMUC Position: Q4 2016 in Review

Northern Trust sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2016, closing a stake of 2,093 shares — an estimated $10K sold.

Northern Trust first reported a position in IMUC in Q2 2013 and held it in 14 quarters. The position peaked at $984K in Q2 2013. 16 funds tracked by Wall St. Rank hold IMUC as of Q4 2016.

  • Northern Trust reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2016 after selling out during the quarter.
  • Northern Trust sold 2,093 ImmunoCellular Therapeutics, Ltd. shares in Q4 2016, an estimated $10K.
  • Northern Trust first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 14 quarters.
  • Northern Trust's ImmunoCellular Therapeutics, Ltd. position peaked at $984K in Q2 2013.
  • 16 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2016.

Based on Northern Trust's 13F filing for Q4 2016, filed 13 Feb 2017.